MIRA
INFORM REPORT
|
Report Date : |
12.05.2012 |
IDENTIFICATION DETAILS
|
Name : |
|
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
20.10.2004 |
|
|
|
|
Com. Reg. No.: |
411700000017692 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Manufacturing and selling pharmaceutical raw material. |
|
|
|
|
No. of Employees : |
90 |
RATING & COMMENTS
|
MIRAs Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name and address
HENAN
TOPFOND SCIENCE AND TECHNOLOGY CO., LTD.
NO. 2 GUANGMING ROAD, ZHUMADIAN CITY,
HENAN PROVINCE, 463000 PR CHINA
TEL: 86 (0) 396-3823605 FAX: 86 (0) 396-3823609
EXECUTIVE SUMMARY
INCORPORATION DATE :
OCT. 20, 2004
REGISTRATION NO. :
411700000017692
REGISTERED LEGAL FORM : LIMITED LIABILITIES CO.
STAFF STRENGTH : 90
REGISTERED CAPITAL : CNY 20,000,000
BUSINESS LINE :
MANUFACTURING AND TRADING
TURNOVER :
N/A
EQUITIES :
N/A
PAYMENT :
AVERAGE
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION :
N/A
OPERATIONAL TREND : STEADY
GENERAL REPUTATION :
AVERAGE
EXCHANGE RATE : CNY 6.30=USD 1
Adopted abbreviations:
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY China Yuan Ren Min Bi
Note: SC is also known as Henan Topfond Technology Co.,
Ltd..
SC was registered as a limited liabilities co. at local Administration for Industry &
Commerce (AIC-The official body of issuing and renewing business license) on
Oct. 20, 2004.
Company Status: Limited Liabilities Co. This form of business in PR
China is defined as a legal person. No more than fifty shareholders
contribute its registered capital jointly. Shareholders bear limited
liability to the extent of shareholding, and the co. is liable for its
debts only to extent of its total assets. The characteristics of this form
of co. are as follows: Upon the establishment of the
co., an investment certificate is issued to the each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SCs registered business scope includes manufacturing
and selling pharmaceutical intermediates and pharmaceutical chemical products;
related technology development & consultation; international trade.
SC
is mainly engaged in manufacturing and selling pharmaceutical raw material.
Mr.
Li Fuzhi has been legal representative
and chairman of SC since 2004.
SC is known
to have approx. 90 employees at present.
SC
is currently operating at the above stated address, and this address houses its
operating office and factory in Zhumadian. Our checks reveal that SC owns the
total premise, but SCs accountant refused to release the gross area.
http://www.topfond.com
The website belongs to Henan Topfond Pharmaceutical Co., Ltd. and it includes
the information on SC and its related companies. The design is professional and
the content is well organized. At present it is both in Chinese and English
versions.
Changes
of its registered information:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registered No. |
4128001002424 |
411700000017692 |
*To what extent is
your company affected by the current Credit Crisis?
SCs management refused to answer this question.
MAIN SHAREHOLDERS:
Name
%
of shareholdings
Henan Topfond Pharmaceutical Co., Ltd. 80
Hangzhou Aumay Biopharmaceutical Co., Ltd. 20
Henan Topfond Pharmaceutical Co., Ltd.
=============================
The said company is a listed company in
Shanghai Stock Exchange Market with the code of 600253.
Registration No. : 410000400013475
Establishment Date: May 4, 1999
Chief Executive: Nian Daming (
Registered Capital: CNY 420,000,000
Add: No. 2 Guangming Road, Zhumadian City,
Henan Province
Tel: 86-396-3823517
Fax: 86-396-3815761
Website: http://www.topfond.com
Email: info@topfond.com
Hangzhou Aumay Biopharmaceutical Co., Ltd.
==================================
Registration No. : 330108000021821
Establishment Date: Feb. 9, 2004
Chief Executive: Han Yijun
Registered Capital: CNY 1,000,000
l
Legal Representative and Chairman:
Mr. Li Fuzhi , senior engineer, born in 1963, he is currently
responsible for the overall management of SC.
Working Experience(s):
From 2004 to present Working in SC as legal representative
and chairman.
Also working in Henan Topfond Pharmaceutical Co.,
Ltd. as general manager and director.
l
General Manager:
Mr. Han Yijun , born in 1966, he is currently
responsible for the daily management of SC.
Working Experience(s):
At present
Working in SC as general manager.
Also working in Hangzhou Aumay Biopharmaceutical Co.,
Ltd. as legal representative.
SC
is mainly engaged in manufacturing and selling pharmaceutical raw material.
SCs products
mainly include: pharmaceutical intermediates, pharmaceutical raw material, and
etc.
SC sources its
materials 100% from domestic market. SC sells 50% of its products in domestic
market, and 50% to overseas market, mainly India.
The buying terms of SC include Check, T/T and Credit of 30-60 days. The
payment terms of SC include Check, L/C, T/T, and Credit of 30-60 days.
According to the above website:
Henan Pharmacy Co., Ltd.
Shanghai Pukang Pharmaceutical Co., Ltd.
Henan Topfond Pharmaceutical Traditional Chinese Medicine Co., Ltd.
Henan Topfond Pharmchem Co., Ltd.
Etc.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for
collection within the last 6 years.
SCs management
declined to release its bank details.
SCs financial
reports were not found during our checks with the local Administration for
Industry and Commerce.
SCs management
declined to release any financial information.
SC is considered small-sized in its line with 6 years operation history.
Credit dealings with SC should be confined into small amount at present.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.64 |
|
|
1 |
Rs.86.42 |
|
Euro |
1 |
Rs.69.28 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.